{{val.symbol}}
{{val.value}}

Stocks trading signals

IndexaCo Signals Marketplace - trading signals with real-time results on the financial markets from professional traders

Blogs

Exxon suspends refinery operation due to strike
Exxon Mobil, stock, Exxon suspends refinery operation due to strike One of the largest oil companies Exxon Mobil Corp. has begun preparations for a gradual shutdown of production at its oil refinery in Foz-sur-Mer in southern France due to a strike launched by trade unions, employees are demanding higher wages to cover inflation. Salary negotiations are scheduled for September. The unions want the management to also commit to paying the bonus. The workers' strike began on June 28.ExxonMobil said in a statement that the situation with the suspension of the plant in difficult conditions in the energy market may affect customers, contractors, suppliers and employees. The company hopes that the problem will be resolved through dialogue and the search for a fair solution.The capacity of the Exxon refinery in Fos-sur-Mer is 7 million tons per year, or about 10% of the production volume in ...
Avatar
Read
Meta expects growth to slow in the second half of the year
Meta Platforms, stock, Meta expects growth to slow in the second half of the year Technology corporation Meta Platforms expects that the second half of the year will become more difficult, as the company faces macroeconomic pressures and problems with data privacy in the advertising segment. The company's management believes that in difficult times, Meta should prioritize more ruthlessly and work flawlessly in conditions of slower growth, when you should not expect a large influx of budget funds and new engineers.The fact that Meta expects growth to slow down is not surprising. The corporation earns mainly from advertising, and due to the crisis and rising inflation in the world, many commercial organizations are reducing advertising costs, which means that the income of social networks, including Meta, will grow more slowly. However, in this case, questions are raised by the fact that it was this year that Meta rebranded and is trying to transform from a social network into a "metaverse", which means that it remains an intrigue how appropriate it was for the corporation to carry out such transformations this year. Meta stock quotes on the premarket are falling by 0.4% today.In addition, Meta Platforms has lowered its target for recruiting engineers this year to 6000-7000, compared to the original plan of 10 thousand new engineers. CEO Mark Zuckerberg has warned employees to prepare for a deep economic downturn."If I had to bet, I'd say it could be one of the worst downturns we've seen in recent history," Zuckerberg told workers at a weekly Q&A ...
Avatar
Read
Google to Pay $90 million to App Developers to Settle Legal Dispute
Alphabet, stock, Google to Pay $90 million to App Developers to Settle Legal Dispute Google, owned by Alphabet Inc, has agreed to pay $90 million to settle a legal dispute with app developers. Earlier, developers accused Google of using agreements with smartphone manufacturers and technical barriers to make most payments through its Google Play payment system, for the use of which you have to pay a commission of 30%.In addition, Google said it would charge developers a commission of 15% of their first million Google Play Store revenue each year. This began to be done in 2021.As part of the proposed settlement, Google said it would invest $90 million in a fund to support app developers whose annual revenue in 2016-2021 was $2 million or less. The court must approve the proposed agreement.According to Hagens Berman Sobol Shapiro LLP, which represented the interests of the plaintiffs, 48 thousand application developers could apply for $90 million, and the minimum payout amount is $ 250.At the moment, in Washington, Congress is considering a bill that obliges Google and Apple to allow side loading or the practice of downloading applications without using their own stores. Google claims it already allows side loading. The new bill will also prohibit companies from requiring app developers to use Google and Apple payment systems.This is great news for American app developers. Google probably compromised and reached a settlement agreement with application developers without waiting for Congress to pass an appropriate antitrust law, which would probably provide for much larger fines for monopolists than the $90 million paid by Google to developers. Now we can expect the same compromise from Apple, which has already been fined in the Netherlands for monopoly. Alphabet's stock quotes on the premarket are growing very moderately ...
Avatar
Read
US market: overview and forecast for June 1. Macro data increases instability
S&P 500, index, Hang Seng, index, Brent Crude Oil, energetic, Gold, mineral, Apple, stock, Meta Platforms, stock, US market: overview and forecast for June 1. Macro data increases instability The market the day beforeThe session on June 30, the main American stock exchanges ended in the red zone. The S&P 500 lost 0.88%, closing at 3,785 points. Nasdaq and Dow Jones fell by 1.33% and 0.82%, respectively. Eight of the 11 sectors in the S&P 500 ended the day in negative territory. Real estate companies (+0.33%) and utilities (+1.10%), as well as representatives of industry (+0.28%) looked better than the market.Company newsMeta Platforms (META: -1.6%) reported a likely decrease in the growth rate of financial indicators in the second half of the year due to the deterioration of the macroeconomic situation and data privacy issues.Apple Inc (AAPL: -1.8%) has raised the cost of the iPhone in Japan by almost 20%, thereby trying to offset the effect of changes in the exchange rate and rising inflation in the country.We expectThe growth of consumer prices in the eurozone in June, according to Eurostat, accelerated from 8.1% to 8.6% with a consensus of 8.4%. This dynamic is mainly due to record levels of energy prices, although food and services are also noticeably more expensive. Thus, the cost of fuel rose by 41.9%, and the cost of food increased by 11.1%. Inflation excluding the prices of these two categories of goods accelerated from 4.4% in May to 4.6%, which is still more than twice the ECB's target of 2%. However, the indicator excluding alcohol and tobacco dropped by 3.7% from 3.8%. The European regulator continues to keep the key rate at a minimum, although other central banks launched monetary policy tightening programs a few months ago. The ECB plans to start a rate hike cycle in July (according to preliminary data, by 25 bps). At the same time, statistics for June, indicating a continued acceleration of inflation, serves as a reason to raise the rate by 50 bps in September.In Germany, an increase in the number of unemployed was recorded by 133 thousand, to 2.4 million, although analysts expected a decrease in this indicator by 5 thousand. In turn, in the United States, the number of initial applications for unemployment benefits for the week ended June 25 decreased by 2 thousand, to 231 thousand, with a consensus of 234 thousand. In our opinion, employment growth in the States has almost stopped, so in the coming weeks statistics will reflect the deterioration in this segment. However, unemployment remains low.The yield of two- and ten-year treasuries decreased by 14 and 12 bps - to 2.93% and 2.97%, respectively.Trading on July 1 at most sites in Southeast Asia ended in the red zone. China's CSI 300 lost 0.41%, Japan's Nikkei 225 dropped 1.73%, although Hong Kong's Hang Seng remained unchanged.Brent crude futures are quoted at $108 per barrel. Gold is trading at $1,794 per troy ounce.In our opinion, the S&P 500 will hold the upcoming session in the range of 3750-3800 points.MacrostatisticsThere are no plans to publish important statistics today.Sentiment IndexThe sentiment index remained unchanged.Technical pictureSince the beginning of the year, the S&P 500 has adjusted down by 26%, including 19% for the second quarter. This was one of the worst results in the history of this statistics. However, in the coming weeks, the market may begin to play rebalancing in stocks by portfolio managers. The nearest support for the broad market index is in the range of 3600-3660 ...
Avatar
Read

Articles about financial markets

You can pay with cryptocurrency: which companies accept crypto in 2022
Ethereum/USD, cryptocurrency, Bitcoin/USD, cryptocurrency, Visa, stock, MasterCard, stock, Coca-Cola, stock, PayPal, stock, Shopify, stock, You can pay with cryptocurrency: which companies accept crypto in 2022 The governor of the Bank of England, Andrew Bailey, said that bitcoin is impractical as a means of payment. While cryptocurrencies are not being calculated massively. But today, large companies not only use blockchain, but also accept crypto as payment:Coca-Cola. In 2020, the corporation's Asia-Pacific division announced that it would allow customers in Australia and New Zealand to buy drinks with bitcoin and other coins. Payment is available through devices that accept digital payments.PayPal is the first payment system to add cryptocurrency for transactions. The company acts as an intermediary: the service will exchange cryptocurrency for ordinary dollars at the internal exchange rate, which already includes the cost of conversion.Visa and Mastercard, following PayPal, thought about the possibility of conducting transactions with cryptocurrencies. The systems focus on stablecoins, which have collateral in the form of real assets.Shopify is a platform for creating online stores. Thanks to the developers, the owners of these stores can accept cryptocurrency.Emirates. The airline from the UAE intends to accept bitcoins as payment. Moreover, Emirates will add its own NFT tokens to the site. This is not the first airline operating with cryptocurrencies. Latvian airBaltic has been selling tickets for the crypt for several years.Balenciaga, Gucci, Tag Heuer are also starting to accept cryptocurrency. Moreover, the new payment method will be available not only online, but also in regular stores using QR codes. And the first major retailer that started accepting the crypt was Overstock.Brazilian developer Gafisa announced that now an apartment can be bought for bitcoins. So the company wants to attract investors from other countries, and the cryptocurrency helps to transfer funds quickly and ...
Read
The US-Russian sanctions war: what threatens the semiconductor market?
Intel, stock, The US-Russian sanctions war: what threatens the semiconductor market? Against the background of geopolitical tensions around Ukraine, the US and Russian authorities are considering plans for possible sanctions against each other. Reuters previously reported that the White House is thinking about a complete ban on exports to Russia of semiconductors manufactured using American technologies. Such a ban may be imposed in the event of an invasion of Ukraine by the Russian Federation.At the same time, the Biden administration warned semiconductor manufacturers: they may face a shortage of the main components for the production of chips, namely C4F6 gas, neon and palladium.Neon is used to produce lasers that are used in microchips. Palladium is used in sensors and memory chips. And all this is largely supplied to the USA from Russia.According to the Techcet research group, neon is a byproduct of Russian steel production. Then it is exported to Ukraine, where it is additionally cleaned, and from there it is sent to the USA. If we talk about specific figures, 35% of palladium supplied to the USA is produced in Russia, and Ukraine accounts for more than 90% of neon supplies to the USA. If the United States restricts the import of semiconductors, Russia in response to this may restrict the import of raw materials for their production.What is the result?If the United States implements such a scenario, then prices for all electronics, in particular smartphones, laptops and PCs, will increase significantly. At the same time, if Russia restricts the supply of palladium and neon, the global shortage of semiconductors that we are currently seeing will only worsen. Market participants expect that in such a scenario, supply chains will not completely stop, but prices and the shortage of components will increase significantly.Against the background of all the news, some chip manufacturers have already begun to revise their supply chains in order to replace imports from Russia with more reliable suppliers. Although Intel (INTC), one of the largest processor manufacturers, said that it does not expect any influence of geopolitics on neon supplies.Opinion of analystsAll of the above is still guesswork and analysis of possible scenarios that can only be realized in the worst case. Most likely, all this will remain at the discussion stage, since an invasion scenario is unlikely.Despite this, a number of changes may occur in the semiconductor industry at the moment. Manufacturers will review their supply chains, which may harm Russian export companies, in particular, Norilsk Nickel (GMKN).Also, due to the alarming news, the prices of neon and palladium can fluctuate greatly. For example, in the early spring of 2014, against the background of unrest in Ukraine, neon prices increased by 600% at the moment. If this growth is repeated, the costs of semiconductor manufacturers may increase, which will worsen the shortage of ...
Read
The main trends of pharmaceutical corporations in 2022
JPMorgan Chase, stock, Pfizer, stock, Moderna, stock, The main trends of pharmaceutical corporations in 2022 The JPMorgan Chase & Co (JPM) annual healthcare conference ended in San Francisco on January 13. This event with a forty-year history is considered one of the most significant in the medical community: pharmaceutical company executives participate in it, important statements about mergers and acquisitions are made on its site, new drugs are presented and breakthrough research is announced.Taking into account the new realities, for the second year in a row, the event is held in an online format. Let's list the most interesting industry trends that were outlined in the speakers' speeches.The use of RNA is recognized as the main trend in pharmacologyRibonucleic acid (RNA) is one of the three main macromolecules in the cells of all living organisms. Although the functions of RNA are not yet fully understood, studies show that this acid plays an important role in the coding and regulation of genes.Ribonucleic acid has attracted increased attention in connection with the development of vaccines against Covid-19. The previous generation of vaccines involved the introduction of a weakened virus into the body to form a subsequent immune response. Moderna (MRNA) and Pfizer (PFE) vaccines, created on the basis of informational RNA, work differently: they ”teach" human cells to produce a protein that triggers an immune response to prevent infection with coronavirus. Thus, the immune system of a vaccinated person is trained to recognize a protein containing Covid-19 and produce antibodies to it.As part of the conference, Pfizer announced the conclusion of three agreements with smaller industry players to accelerate RNA developments. The company sees a huge potential for RNA-based drugs - in particular, in the treatment of cancer and rare diseases. Amgen's interest in collaborating with Arrakis Therapeutics in the study of RNA is widely discussed, which could result in an order for several billion dollars for the latter. Pharmaceutical giants Johnson & Johnson (JNJ) and Eli Lilly (LLY) have so far limited themselves to restrained statements that they are exploring the possibilities of RNA technologies.Coronavirus pushes for partnerships instead of mergersFor the second year in a row, the healthcare sector has not heard about major deals. The coronavirus has shuffled all the cards. Previously, when a breakthrough technology was discovered, a pioneer was usually expected to be absorbed at a premium to the market, but the pandemic has taught companies to think in a new way, and now they are increasingly inclined to partnerships.The most telling example was the collaboration in the development of a coronavirus vaccine between Pfizer and BioNTech (BNTX). Through partnership, large players actually place an order for development to specialized companies with lower turnover. As a result, both sides benefit: pharmaceutical giants save money, and their partners receive orders and financing.Covid-19 ComebackHaving not had time to fully vaccinate against Covid-19, humanity faced a threat in the form of a new and more contagious variant of the coronavirus - "omicron". A strain from South Africa sets anti-records for morbidity in developed countries, involving pharmaceutical giants in a new development race.Some companies at the conference reported on the supply of their drugs against coronavirus. So, Moderna reported that its sales in 2021 amounted to $ 18.5 billion. GlaxoSmithKline (GSK), in partnership with Vir Biotechnology (VIR), reported on the supply to the US government of 600 thousand doses of the drug for the treatment of Covid-19 sotrivimab. Novavax (NVAX) announced that it has already made the first shipments to Europe of its Covid-19 vaccine, but did not specify the volume of orders. And Gilead Sciences (GILD) has informed that its drug remdesivir may soon be approved by the US regulator for the treatment of coronavirus.As for the development of drugs aimed directly against the omicron strain, only Regeneron (REGN) and Pfizer have made statements about this. Regeneron is going to test the treatment of omicron with antibodies in the first quarter, and Pfizer spoke about the progress in creating a new vaccine against Covid-19, which will also work against the new strain.There is an opinion that omicron as an opportunity rather than a threat. Perhaps omicron is our salvation from coronavirus restrictions, since the body of vaccinated people, having met with a new strain of virus from South Africa, gives an immune response, which can be considered as an alternative to booster vaccination. Which, in a global effect, can give massive protection against coronavirus infection.Patent diversificationLarge pharmaceutical companies are in a hurry to reassure investors who are beginning to pay attention to the patent terms of drugs that occupy a large share in their sales.As a rule, after the expiration of a patent for a particular drug, the market is flooded with its cheaper copies, which significantly reduces the revenue of the manufacturer of the original drug. Therefore, investors expect a diversified portfolio of developments from pharmaceutical giants, which will include not only expensive cancer drugs, but also a wide range of medicines for other diseases.For example, the patent of the anti-cancer drug from Merck & Co (MRK) Keytruda expires in 2028. Total sales of this drug for 2020 amounted to $14.4 billion, which accounted for 30% of Merck's revenue. If the company does not explain to investors before the expiration of the exclusivity period how it is going to compensate for the upcoming "loss” of sales volumes, the market reaction can be very negative.Analysts' opinionAn endless "arms race" continues in the pharmaceutical sector. Since breakthrough technologies and patents provide only a temporary competitive advantage, companies have to constantly set themselves new and new goals.However, the JPMorgan conference reflected some changes in the behavior of both pharmaceutical companies and their investors. Industry representatives confirmed their propensity to create partnerships, and investors confirmed their demands for diversification of development portfolios.The most obvious new trend among the elite of pharmacology has been the use of ribonucleic acid to encode the human immune system. It is assumed that with the proper development of technology, scientists will be able not only to achieve the necessary immune response to various infectious diseases, but also to eliminate defects in hormones or blood quality.And the main intrigue remains who will be the first to develop a vaccine against the omicron strain. Leading pharmaceutical giants are studying its characteristics, causes of origin and the reaction of previously vaccinated people to it. Thus, the beginning of this year is similar to the beginning of the previous one. Back then, we were also on the verge of creating a working version of the vaccine and watched the deadly virus walk around the planet ...
Read
About the trends of 2022
Litecoin/USD, cryptocurrency, Ethereum/USD, cryptocurrency, Bitcoin/USD, cryptocurrency, Pfizer, stock, Moderna, stock, About the trends of 2022 A couple of steps away from the new year, many are trying to predict the direction of market winds over the next year, and maybe several. We have also analyzed promising ideas of stock exchanges, and today we will share them with you. In general, everything promising in the coming year is connected with the healthcare sector. Next, let's talk about the two most promising companies in this segment.NovavaxNovavax company was one of the first to enter the championship in the development and creation of a vaccine, but in this case it is still far from the podium. Does the company have real prospects? Let's talk about this further.At the beginning of the year, many experts argued that it was simply not advisable to get involved in the company's struggle. This was due to the fact that there were already many manufacturers of similar drugs, and there was not enough space for new ones. As a result, the experts' "verdict" turned out to be reckless, and today many are confident that the company's assets are among the most attractive in the coming year.The vaccine was one of the first to be released in Europe. It is based on a protein, which in the future can become an alternative for patients who refuse to be vaccinated by Pfizer and Moderna, developed on the basis of RNA.In the spring of 2021, she presented the results of testing a new vaccine to the world, and in mid-summer, repeated tests were conducted in America. The effectiveness of the drug according to the test results ranges from 89.7% to 90.4%. This high indicator allowed the drug to get into the top three most effective, and the company to become a leader in the world market of manufacturers.Immediately after the publication of the results, it was expected that the company's assets should increase in value, but problems with bureaucratic hitches and permission to use the vaccine on world markets led to the fact that the share price remained in place, and subsequently even declined.Different sources explain this fall in different ways. Some argue that there are no special technological lines for the production of the drug in the United States. Others are sure that the drug simply does not meet the standards established in the state, contains unnecessary impurities that can cause a lot of side effects.Today, the drug is recognized in several countries of the world, including Indonesia, India. The vaccine has the permission of the WHO and the euroregulator, together with the submission of the application, it has received permission in several other countries.Today Novavax is awaiting regulatory approval in many countries around the world, including Australia, Canada, South Korea, and the United Kingdom. To accelerate the production of the drug, the company is sponsored by a number of large-scale organizations, including the Gates Foundation and even the American government.If new strains of coronavirus continue to appear, the disease will be transferred to the category of endemic. That is why vaccination will very soon become a routine procedure, and it is also likely that the demand for combined drugs will grow, which the company is currently testing.It is not enough to be able to treat well, you also need to correctly diagnose diseases. That is why next we will talk about the manufacturer of medical equipment for diagnostics.Thermo Fisher ScientificThermo Fisher Scientific is geographically located in Massachusetts. It is one of the leaders in the production of diagnostic tools and equipment used in laboratory and outpatient settings, as well as consumables. The production of coronavirus vaccines and medicines for this pathology is considered to be an equally significant area of activity of the enterprise. From the beginning of the pandemic to the present time, the demand for the company's products remains at a height, so the company today occupies a leading position in the field of medicine.In the spring of 2021, the International Health Association granted the company a license to produce SARS-CoV-2, a test for detecting covid-19. The volume of revenue received only from anti-weed products today has already amounted to $2.05 billion. With the emergence of new strains of coronavirus, the demand for the company's products will only grow.The TMO quarterly report, released on October 27, turned out to be quite strong. Revenue exceeded last year's figure by 15%, as well as by $ 1.2 billion in monetary terms. In total, it amounted to 37.1 billion dollars. According to forecasts, the amount of revenue will increase by $1 billion, and will amount to $7.7 billion.The forecast for this indicator was $40.5 billion, which shows the excellent position of the enterprise, especially for modern market realities. The growth of the company's asset price index exceeded the S&P 500, and reached 40%. With great probability, we can say that the group's positions will continue to be stable.Another trend of the century is electric carsThe vast majority of major analysts last year warned against acquiring Nio assets. At that moment, no one could have thought that the company's market capitalization could reach $90 billion. The volume of cars produced at the same time is 20 thousand units annually.However, over the past year, the company has managed to become an industry leader, and excellent financial results are expected in 2022. This is despite supply disruptions and other problems associated with the pandemic. The company has several new products that will help it increase its market share in China, and take a strong position on it.In the autumn of 2021, the number of cars produced by the company reached 10,900 units, which indicates an active growth in demand for cars with an engine capacity of more than 130,000 per year. The company is going to release about 600 thousand units of cars by the end of 2022. Nio's management plans to introduce three new electric cars to the world market. If the sales growth of cars remains at the planned indicators, then Nio may well have the opportunity to bypass Tesla by this parameter. At least in the Chinese market.An important advantage of the enterprise is the already launched Battery-as-a-service or BaaS program. It allows you to make a monthly payment, which allows you to change the battery on an electric car in the future or update the battery charge. It will also be possible to buy a car without a battery, rearranging it from old equipment.This system will allow the company to receive high-margin revenue in the long term. In addition, we should expect an increase in customer loyalty to the products. The company's assets showed a 13% growth in 2020, but during 2021 they managed to fall by 44%. Today they are stable at around $30. We are waiting for strong growth.Basic Attention TokenIt is already impossible to imagine the financial world without cryptocurrency. How to choose correctly between all the options – Bitcoin, Litecoin, Ethereum and others, and not be left out? An interesting option is offered by the Basic Attention Token.Over the past six months, investors' attention has been focused on tokens supporting the application. If we take into account that since the beginning of the year, the growth of bitcoin has approached 73%, then this is a minuscule compared to the start of the Siba-anu meme token, which soared to 47000000%. However, the main investment flow today is considered to be directed to a cryptocurrency that provides support for applications.In the large list of tokens, the Basic Attention Token from Brave Software deserves special attention. In particular, the token is especially attractive for investing for a long period. The company is now managed by B. Eich is the founder of Mozilla and JavaScript.Coins are mined using the Brave browser, where they are obtained by viewing advertising content. The web browser provides a high degree of security due to the built-in ad blocker and functions to block the collection of user data. Allows you to personally view ads released by program partners, as well as earn tokens by viewing it.Throughout December, bears dominated the cryptocurrency market, which negatively affected the VAT. As a result, the price of the token fell by 30% from the historical highs seen at the end of autumn. However, Bravo is confident that the price will recover its indicators very ...
Read
Message sent successfully.
We will contact you soon!